Stock Yards Bank & Trust Co. Grows Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Stock Yards Bank & Trust Co. increased its holdings in Gilead Sciences by an impressive 1,069.8%, owning 25,220 shares worth approximately $2.8 million after purchasing an additional 23,064 shares in the second quarter.
• Insiders at Gilead Sciences, including CFO Andrew D. Dickinson and another executive, sold a combined 5,500 shares on September 15, 2023, reflecting a decrease in their ownership of the stock.
• Gilead Sciences reported a quarterly earnings of $2.01 per share, exceeding analyst estimates, and declared a quarterly dividend of $0.79 per share, amounting to an annualized yield of 2.8%.

Stock Yards Bank & Trust Co. grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1,069.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,220 shares of the biopharmaceutical company's stock after purchasing an additional 23,064 shares during the period. Stock Yards Bank & Trust Co.'s holdings in Gilead Sciences were worth $2,796,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at $25,000. Activest Wealth Management increased its stake in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 227 shares during the period. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at $29,000. Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares during the period. Finally, Core Alternative Capital increased its stake in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. UBS Group raised their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Royal Bank Of Canada lifted their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $117.17.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $112.69 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market cap of $139.83 billion, a PE ratio of 22.45, a P/E/G ratio of 0.75 and a beta of 0.34. The business has a 50-day simple moving average of $114.34 and a two-hundred day simple moving average of $109.92. Gilead Sciences, Inc. has a fifty-two week low of $83.98 and a fifty-two week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.